West Pharmaceutical Services (NYSE:WST) Hits New 1-Year High at $125.15

West Pharmaceutical Services Inc. (NYSE:WST)’s stock price hit a new 52-week high on Friday . The stock traded as high as $125.15 and last traded at $124.63, with a volume of 4840 shares trading hands. The stock had previously closed at $123.58.

Several analysts have recently weighed in on the stock. Zacks Investment Research raised shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Jefferies Financial Group downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 target price on the stock. in a report on Wednesday, May 1st. Finally, William Blair assumed coverage on shares of West Pharmaceutical Services in a report on Tuesday, April 23rd. They issued an “outperform” rating and a $112.16 target price on the stock.

The stock has a market capitalization of $9.20 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 3.80 and a beta of 1.30. The company’s fifty day moving average price is $118.88. The company has a current ratio of 2.88, a quick ratio of 2.13 and a debt-to-equity ratio of 0.19.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.08. West Pharmaceutical Services had a net margin of 12.53% and a return on equity of 16.38%. The business had revenue of $443.50 million for the quarter, compared to the consensus estimate of $431.00 million. During the same quarter in the previous year, the firm earned $0.62 earnings per share. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. As a group, equities analysts predict that West Pharmaceutical Services Inc. will post 2.88 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 24th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend is Tuesday, July 23rd. West Pharmaceutical Services’s dividend payout ratio (DPR) is 21.35%.

In related news, VP Daniel Malone sold 4,458 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $123.03, for a total value of $548,467.74. Following the completion of the sale, the vice president now owns 33,478 shares in the company, valued at $4,118,798.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.70% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in WST. Norges Bank acquired a new position in West Pharmaceutical Services during the fourth quarter worth about $65,643,000. BlackRock Inc. raised its position in shares of West Pharmaceutical Services by 4.5% in the fourth quarter. BlackRock Inc. now owns 6,939,493 shares of the medical instruments supplier’s stock valued at $680,279,000 after buying an additional 298,898 shares during the last quarter. Millennium Management LLC raised its position in shares of West Pharmaceutical Services by 465.9% in the fourth quarter. Millennium Management LLC now owns 151,748 shares of the medical instruments supplier’s stock valued at $14,876,000 after buying an additional 193,221 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of West Pharmaceutical Services by 30.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 691,502 shares of the medical instruments supplier’s stock valued at $67,788,000 after buying an additional 159,814 shares during the last quarter. Finally, Ellis Investment Partners LLC acquired a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $155,000. Hedge funds and other institutional investors own 91.90% of the company’s stock.

West Pharmaceutical Services Company Profile (NYSE:WST)

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Story: Buy-Side Analysts

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.